The NoLymiT team is principal investigator of the European THERAVLINFO project.

THERAVLINFO is an advance in the biomedical translation of preclinical lymphoma knowledge and models generated in IMLINFO (EFA 281/16), in order to improve the survival and quality of life of patients with hematological cancer.

OBJECTIVE: To determine the effectiveness of new immunotherapy treatments through the creation of a NHL tumour bank associated with a 3D culture platform. The project is part of axis 1 of the POCTEFA programme: Boosting innovation and competitiveness.

More informations

Pin It on Pinterest